ABVC BioPharma, Inc.
ABVC
$0.911
$0.0354.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 511.90K | 650.70K | 286.60K | 175.60K | 302.70K |
| Total Other Revenue | -2.30K | -141.00K | -134.40K | -134.40K | -134.40K |
| Total Revenue | 509.60K | 509.80K | 136.40K | 25.40K | 152.50K |
| Cost of Revenue | 800.00 | 140.00K | 169.30K | 242.10K | 302.00K |
| Gross Profit | 508.90K | 369.90K | -32.80K | -216.70K | -149.60K |
| SG&A Expenses | 5.03M | 5.03M | 6.73M | 7.29M | 5.55M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 28.60K | -18.10K | 9.60K | 9.60K | 9.60K |
| Total Operating Expenses | 5.24M | 5.37M | 7.23M | 8.34M | 6.93M |
| Operating Income | -4.73M | -4.86M | -7.10M | -8.31M | -6.78M |
| Income Before Tax | -5.37M | -6.02M | -9.26M | -10.11M | -8.02M |
| Income Tax Expenses | -110.50K | 64.80K | 63.40K | 256.00K | 256.00K |
| Earnings from Continuing Operations | -5.26 | -6.09 | -9.32 | -10.36 | -8.28 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 356.10K | 572.70K | 675.60K | 467.30K | 492.80K |
| Net Income | -4.90M | -5.52M | -8.65M | -9.90M | -7.79M |
| EBIT | -4.73M | -4.86M | -7.10M | -8.31M | -6.78M |
| EBITDA | -4.70M | -4.84M | -7.07M | -8.29M | -6.75M |
| EPS Basic | -0.49 | -0.57 | -1.37 | -1.96 | -2.11 |
| Normalized Basic EPS | -0.30 | -0.30 | -0.79 | -1.14 | -1.23 |
| EPS Diluted | -0.50 | -0.57 | -1.37 | -1.97 | -2.11 |
| Normalized Diluted EPS | -0.30 | -0.30 | -0.79 | -1.14 | -1.23 |
| Average Basic Shares Outstanding | 46.67M | 40.14M | 31.79M | 23.78M | 17.35M |
| Average Diluted Shares Outstanding | 46.67M | 40.14M | 31.79M | 23.78M | 17.35M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |